Scienture Holdings, Inc. (SCNX)
| Market Cap | 4.80M -72.8% |
| Revenue (ttm) | 821,315 +540.6% |
| Net Income | -37.95M |
| EPS | -32.46 |
| Shares Out | 1.64M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 76,084 |
| Open | 3.390 |
| Previous Close | 3.360 |
| Day's Range | 2.810 - 3.390 |
| 52-Week Range | 2.810 - 65.000 |
| Beta | 4.08 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 12, 2026 |
About SCNX
Scienture Holdings, Inc. operates as pharmaceutical company that focuses on development and commercialization of products for the treatment of central nervous system and cardiovascular diseases in the United States. The company develops SCN-102, an oral liquid formulation of losartan potassium that is in phase 1 for the treatment of hypertension, diabetic nephropathy, and reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy; and SCN-104, a multi-dose dihydroergotamine mesylate (DHE) injection pen. It al... [Read more]
Financial Performance
Financial StatementsNews
DataMeds Applauds FDA's Proposed Interim Access Policy for Compounding Using Certain Peptides and Provides Corexa Health's Peptides Roadmap
Corexa Health's three divisions - pharmacy, distribution, and tech & hub - positioned to serve the emerging compounded peptide market TAMPA, FL / ACCESS Newswire / October 16, 2026 / DataMeds AI, Inc....
DataMEDS Si Licenses U.S. Rights To Reboot Health AI's Direct-To-Consumer GLP-1 Weight Management Platform
Platform to be integrated into Health Lives Here app as a subscription offering TAMPA, FL / ACCESS Newswire / October 14, 2026 / DataMeds AI, Inc. (NASDAQ:MEDS) ("DataMeds AI," "DataMEDS SI," "DataMED...
Scienture reports preliminary Q3 revenue $1.22M, consensus $1.58M
“These preliminary third-quarter revenue results mark a significant inflection point for Scienture (SCNX), demonstrating the accelerating commercial momentum of our expanding pharmaceutical portfolio,...
SCIENTURE Reports Approximately $1.22 Million in Unaudited Preliminary Q3 2026 Revenue, Achieving 256% Sequential Growth
Continued Arbli ™ sales growth, combined with REZENOPY ™ commercial launch in August 2026 and initial wholesale shipments, drives significant sequential revenue growth
DataMEDS SI Provides Business Update On CLIA Lab Helomics And Its Super Intelligence Predictive Oncology Division
Leading Health IT Company has Implemented Cost Control Measures and Refocused Remaining Workforce Towards ChemoFx® Commercialization with Hospital Systems, HMOs, GPOs and Cancer Centers TAMPA, FL / AC...
DataMEDS SI Announces Helomics Receives Medicaid Coverage Policy For Chemofx(R) Assay In Gynecologic Cancers
Humana adds ChemoFx® to its Medicaid Pharmacogenomics Testing coverage policy TAMPA, FL / ACCESS Newswire / October 12, 2026 / DataMeds AI, Inc . (NASDAQ:MEDS) ("DataMeds AI," "DataMEDS SI," "DataMEDS...
Datameds AI Files DBAs Datameds SI And Corexa Health SI And Reminds Shareholders Of Record As Of August 7, 2026 Of Dream Bowl Meme Coin I Payment
Healthcare IT Company and its Subsidiary Undertake Action Following US Government's Updated Nomenclature TAMPA, FL / ACCESS Newswire / October 5, 2026 / DataMeds AI, Inc . (NASDAQ:MEDS) ("DataMeds AI,...
Scienture Holdings Inc trading halted, news pending
19:50 EDT Scienture (SCNX) Holdings Inc trading halted, news pending
Scienture’s Arbli added to formularies at 3 U.S. pediatric academic med centers
Scienture (SCNX) announced that Arbli Oral Suspension, 10 mg/mL has been added to the formulary of three U.S. pediatric academic medical centers and hospitals specializing in the treatment of children...
SCIENTURE Announces Arbli™ Added to Formularies at Three Leading U.S. Pediatric Academic Medical Centers and Hospitals
Major Institutional Formulary Win Expands Arbli ™ 's Presence in Pediatric Care as Wholesale Orders Continue to Increase Sequentially
DataMeds AI's Corexa Pharmacy Surpasses $1 Million In Monthly Revenue
September 2026 revenue up more than 66 percent from July 2026 with expansion of retail customer base and Tollo Health pharmaceutical-adjunct product launches TAMPA, FL / ACCESS Newswire / October 1, 2...
Scienture announces reverse stock split
Scienture (SCNX) announced that it has determined to effect a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-25. The reverse stock split is…
Scienture Holdings, Inc. Announces Reverse Stock Split
COMMACK, NY, Sept. 30, 2026 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) (“Scienture”), a holding company for existing and planned pharmaceutical operating companies focused on providin...
DataMeds AI and Tollo Health Announce Launch of 'Health Lives Here' Mobile Application
Healthcare IT Company and Nutritional Products Maker to Work with NFL Alumni Health to Drive Awareness of GLP-1 Telehealth and Pharmacy Services TAMPA, FL / ACCESS Newswire / September 28, 2026 / Data...
DataMEDS AI To Present At 2026 National Telehealth and Virtual Care Summit
Interim Co-CEO to Discuss Growing Patient Desire to Own Health Data TAMPA, FL / ACCESS Newswire / September 25, 2026 / DataMeds AI, Inc. (NASDAQ:MEDS) ("DataMeds AI," "DataMEDS," or the "Company"), a ...
Scienture expands commercial reach of Rexenopy to Addiction Treatment Centers
Scienture (SCNX) announced that its wholly owned subsidiary, Scienture, has entered into an exclusive Sales, Marketing and Distribution Agreement with a distribution partner to provide opioid and subs...
SCIENTURE Expands Commercial Reach of REZENOPY™ to Addiction Treatment Centers through an Agreement with a Distribution Partner
Agreement provides dedicated commercial channel for REZENOPY ™ across approximately 2,000 OTP (Opioid Treatment Program) Clinics and other Addiction Treatment Center Networks in the United States
DataMEDS AI Unveils New Corporate Website
Updated Website Aligns with Pending Marketing Initiatives Following Recent Acquisition of Helomics CLIA-certified Laboratory and Litigation Settlement TAMPA, FL / ACCESS Newswire / September 21, 2026 ...
DataMeds AI Litigation Settlement Extinguishes ~$19 million In Liabilities and Retires 364,099 Common Sharessked
TAMPA, FL / ACCESS Newswire / September 18, 2026 / DataMeds AI, Inc. (NASDAQ:MEDS) ("DataMeds AI," "DataMEDS," or the "Company"), a healthcare company leveraging its Health IT and physical infrastruct...
This AI stock experienced a 5x rally on Wednesday
DataMeds AI (MEDS) shares ripped higher on Wednesday morning as the company completed its acquisition of Helomics AI cancer diagnostics laboratory and precision oncology contract research organization...
DataMEDS, AI. Acquires Helomics AI Cancer Diagnostics Lab and Precision Oncology CRO Businesses from Axe Compute
Acquisition Provides Operational Capital to Drive Health Lives Here Campaign and Expand Services into Cancer Management PITTSBURGH, PA / ACCESS Newswire / September 15, 2026 / DataMEDS AI, Inc. (NASDA...
SCIENTURE to Present at the H.C. Wainwright 28th Annual Global Investment Conference on September 14, 2026
Management to Highlight Growing Commercial Momentum of Arbli ™ and the Commercial Launch of REZENOPY ™
Datameds, AI., and Tollo Health Partner with the NFL Alumni Association for Health Lives Here National Campaign Rollout
Leading Healthcare IT Company and Former NFL Players Will Work Together to Provide Rural Communities Access to Telehealth and Pharmacy-based Services Through Health Lives Here Mobile App TAMPA, FL / A...
DataMeds AI and Tollo Health Announce Fall 2026 Cold & Flu #Back2School50% Marketing Campaign for Viral Infections Medical Food Galectovid(TM)
50% off available online at www.TolloHealth.Shop and www.CorexaRx.com Soon to become available at Health Lives Here™ pharmacies and on Amazon.com TAMPA, FL / ACCESS Newswire / August 27, 2026 / Dat...
DataMeds AI Reports Second Quarter 2026 Financials and Provides Business Update
Revenues grew 14% reaching $1.779M in Q2/26, beating management projections Corporate name change from Wellgistics Health, Inc. to DataMeds AI, Inc. in July 2026, which led to stock symbol change from...